日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Bimekizumab: Short-Term Effectiveness and Safety in Real Clinical Practice in Andalucia, Spain

Bimekizumab：西班牙安达卢西亚真实临床实践中的短期疗效和安全性

期刊:Life-Basel
影响因子:3.4
doi:10.3390/life14030281
Ruiz-Villaverde, Ricardo; Rodriguez-Fernandez-Freire, Lourdes; Cebolla-Verdugo, Marta; Prados-Carmona, Alvaro; Hernández-Montoya, Carlos; Armario-Hita, José Carlos; Galán-Gutiérrez, Manuel
发表日期：2024
文献求助 收藏

Super-Responders in Moderate-Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives

古塞库单抗治疗中重度银屑病超敏反应者：误区、现实与未来展望

期刊:Life-Basel
影响因子:3.4
doi:10.3390/life12091412
Ruiz-Villaverde, Ricardo; Vasquez-Chinchay, Fiorella; Rodriguez-Fernandez-Freire, Lourdes; C Armario-Hita, Jose; Pérez-Gil, Amalia; Galán-Gutiérrez, Manuel
银屑病
发表日期：2022
文献求助 收藏

Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines

Risankizumab：在西班牙安达卢西亚真实临床实践中，根据西班牙银屑病指南的治疗目标，评估其中期（52 周）疗效、安全性和生存率

期刊:Life-Basel
影响因子:3.4
doi:10.3390/life12111883
Ruiz-Villaverde, Ricardo; Rodriguez-Fernandez-Freire, Lourdes; Pérez-Gil, Amalia; Font-Ugalde, Pilar; Galán-Gutiérrez, Manuel
银屑病
发表日期：2022
文献求助 收藏

Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study

古塞库单抗治疗中重度银屑病患者的疗效、生存率和安全性及其与基线特征的关系：一项队列研究

期刊:F1000Research
影响因子:
doi:10.12688/f1000research.122945.2
Ruiz-Villaverde, Ricardo; Rodriguez-Fernandez-Freire, Lourdes; Armario-Hita, Jose C; Pérez-Gil, Amalia; Vasquez Chinchay, Fiorella; Galán-Gutiérrez, Manuel
银屑病
发表日期：2022
文献求助 收藏